Abstract. Development and characterization of dexamethasone (DEX)-encapsulated polymeric nanomicelles have been reported. A low molecular weight di-block copolymer was synthesized and characterized for its structure, molecular weights, critical micelle concentration (CMC), and cytotoxicity in ocular cells. In order to delineate the effects of drug-polymer interactions on drug solubilization in micelle core, a response surface methodology was generated with the help of SAS 9.02 (exploratory model). The method for preparing micelle was modified based on the results obtained from exploratory model. The formulation was optimized by response surface methodology (optimization model) to achieve DEX solubility of above 1 mg/mL. The optimized formulation was characterized for DEX solubility, nanomicelle size, polydispersity index, surface morphology, in vitro transport across conjunctival cell line, and ex vivo transport across excised rabbit sclera. Nanomicelles exhibited average sizes in range of 25-30 nm with unimodel size distribution and low polydispersity of 0.125. Nanomicelles increased DEX permeability by 2 times across conjunctival cell line and by 2.5 times across the excised rabbit sclera as compared to DEX suspension. A design of experiment (DOE) strategy was successfully applied to understand the effects of drug-polymer interaction on drug solubility. DOE was also employed to achieve optimal formulation with high DEX solubility. Nanomicellar formulation significantly enhanced DEX permeability across the excised rabbit sclera. Therefore, nanomicellar formulation may provide therapeutic levels in the back of the eye following topical administration.
INTRODUCTION
Uveitis is an intraocular inflammatory disease responsible for 10-15% blindness in developed countries (1) . It affects intermediate and/or posterior segments involving sections of choroid and retina, which often results in blindness. Steroids have been a mainstay treatment option for this inflammatory condition (2) (3) (4) (5) . Traditionally, steroids are administered by systemic routes. However, systemic administrations of steroid are not well tolerated by all patients (5, 6) . Topical drops of steroids are well tolerated, but drug levels achieved in intermediate and posterior ocular segments are often subtherapeutic (5, 6) . In the past decade, clinically recalcitrant uveitis has been treated by steroids administered as intravitreal (IVT) injections (4, 7, 8) . IVT injections are associated with numerous side effects including retinal detachment, endophthalmitis, cataract, and elevated intraocular pressure (7, 9) .
Topical administration is the most patient-compliant route. Nonetheless, drug delivery to intermediate and posterior segment via topical drops is a significant challenge. Less than 5% of topically administered dose reaches ocular segments (such as retina and vitreous) owning to static and dynamic barriers (2, 10) . Typical instillation volume for topically administered formulation is usually less than 40-50 μL, to avoid drug loss via reflux tearing and nasolacrimal drainage. Low instillation volume entails steroidal agents to be solubilized at higher concentration in aqueous solution in order to achieve therapeutic drug level in intermediate and/or posterior segments. However, steroids are hydrophobic in nature with poor aqueous solubility and cannot be dissolved at higher concentrations in aqueous solution.
Nanocarriers such as liposomes and nanomicelles are capable of solubilizing highly hydrophobic drugs in aqueous medium (11) (12) (13) (14) . Micelles represent supramolecular Electronic supplementary material The online version of this article (doi:10.1208/s12249-014-0100-4) contains supplementary material, which is available to authorized users. arrangement of amphiphilic polymeric systems with typical size in range 10-100 nm. They have been investigated extensively to solubilize hydrophobic drugs. Polymeric micelles can be prepared with various di-block polymers consisting of hydrophobic and hydrophilic units. Transport of nanocarriers across the static and dynamic barriers depends on the particle size (15) . Recently, Inokuchi et al. have illustrated that the liposome size of ∼110 nm resulted in higher coumarin-6 accumulation in posterior segment following topical administration (16) . A topical eye drop solution of steroids can be formulated by dissolving these compounds inside hydrophobic core of the polymeric micelles. We hypothesize that nanomicelles of mean size less than 50 nm may effectively overcome the static and dynamic barriers to provide therapeutic drug concentration in the intermediate and posterior uvea.
Recently, there is a growing interest in utilizing design of experiment (DOE) to optimize formulations. Experimental designs such as a three-level response surface methodology may explain the influence of individual factors and their interactions on response variables. In this manuscript, we have successfully employed DOE to understand the process parameters (dexamethasone (DEX)-polymer interaction in this case) on drug solubilization in micelles. Based on the information obtained from exploratory model, we modified the micelle preparation method to develop optimal formulation. The optimal formulation was characterized for micelle size, drug solubility, surface morphology, and in vitro drug release. Furthermore, in vitro transports across conjunctival cells and ex vivo transport across the excised rabbit sclera were also carried out for optimized formulation.
MATERIAL AND METHODS

Materials
Dexamethasone (purity ≥99%) was obtained from Enzo Life Sciences (Farmingdale, NY). ε-Caprolactone, stannous octoate, and methoxy poly(ethylene glycol) (mPEG; molecular weight (Mw) 2,000) were procured from Sigma Chemicals (St. Louis, MO, USA). Acetonitrile, methanol, D6-chloroform, D6-DMSO, anhydrous diethylether, and tert-butyl methyl ether (TBME) were also obtained from Sigma Chemicals (St. Louis, MO, USA) and used without further purification. Human conjunctival epithelial cell (HCE cell, Chang cell, CCL-20.2) was procured from the American Type Culture Collection (ATCC). Human corneal epithelial cell (SV40) was a generous gift from Dr. Araki-Sasaki (Kinki Central Hospital, Japan). Lactate dehydrogenase (LDH) and CellTiter 96® AQ ueous NonRadioactive Cell Proliferation (MTS) assay kits were purchased from Fisher Scientific Inc. and Promega Corp., respectively. Millipore™ Millex™ sterile syringe filters made of durapore hydrophilic polyvinylidene fluoride (PVDF) (pore size 0.22 μm) were obtained from Fisher Scientific.
Methods
Synthesis of di-Block Polymer
The di-block polymer was synthesized by ring opening polymerization by following published protocol with necessary modifications (17, 18) . Briefly, monomer ε-caprolatone (39.4 mmol), initiator mPEG (3 mmol), and catalyst stannous octoate (0.5% w/w of reactants) were added in a reaction vessel prefilled with nitrogen. Toluene (5 mL) was added to reactants, followed by heating at 100°C under vacuum until the total volume was reduced to initial volume. The temperature was then raised to 130°C. After 12 h, the reaction mixture was cooled down to room temperature (RT). The reaction mixture was dissolved in dichloromethane and precipitated in cold anhydrous ether. The final product was filtered and dried under vacuum. The polymer was characterized by 1 H-NMR (Varian 400 MHz), IR spectroscopy, and gel permeation chromatography for structure and molecular weight determinations.
Critical Micelle Concentration (CMC)
CMC was determined using pyrene as a hydrophobic fluorescent probe following a previously published method with modifications (19, 20) . Briefly, serial dilutions of polymer from 1,000 to 0.27 μg/mL were prepared in chloroform. Each dilution was added with 30 μg pyrene in chloroform. The chloroform solution, containing polymer and pyrene, was vortexed and dried under vacuum. DDW was added to the dried samples and vortexed for 1 min. Solutions were incubated at 37°C for 12 h then syringe-filtered (0.25 μm) to remove undissolved pyrene. Filtrates were measured for pyrene fluorescence. Samples were excited at 330 nm and emissions were measured at 372 nm (I 2 ) and 392 nm (I 1 ). A ratio of emission intensities (I 2 /I 1 ) was plotted against polymer concentrations to calculate CMC. The polymer concentration where we observed a sharp increase in I 2 /I 1 ratio was considered as CMC for the polymer.
Cell Culture
HCE cells were maintained in a cell culture flask containing Minimum Essential Medium (MEM) Earle's Balanced Salt Solution (BSS) medium supplemented with 10% fetal bovine serum (FBS), 100 U/L of penicillin, 100 mg/L of streptomycin, sodium bicarbonate (2.2 mg/mL), and 2 mM L-glutamine. Human corneal epithelial cells (SV40 cells) were cultured in DMEM/F-12 medium supplemented with 15% (v/v) heat-inactivated FBS, 22 mM NaHCO 3 , 15 mM HEPES and 5 mg/L insulin, 10 μg/L human epidermal growth factor, 100 mg penicillin, and 100 mg streptomycin each. Both cell lines were incubated at 37°C, 5% CO 2 , and 98% humidity.
In Vitro Cytotoxicity
Cytotoxicity studies were performed for newly synthesized polymer by MTS and LDH assays. Polymer concentrations of 25, 50, and 100 mg/mL were examined for cytotoxicity in both conjunctival (HCE cells) and corneal (SV40 cells) cell lines. The highest concentration of polymer in DOE was 53.8 mg/mL. The polymer concentrations were chosen such that it would cover the highest concentration of polymer in the final formulation obtained by DOE. We went up to 100 mg/ mL concentration of polymer to make certain that there is no toxicity even at higher concentration.
MTS Assay. MTS assay was performed according to previously published protocol with minor modifications (21) .
Polymer solutions were prepared in culture medium and sterilized by filtration with 0.2-μm syringe filters. In brief, HCE or SV40 cells at a density of 10 4 per well were cultured in a 96-well plate and incubated for 24 h. Polymer solutions were prepared in culture medium and sterilized by filtration with 0.2-μm syringe filters. Following incubation, medium was removed and cells were exposed to three different concentrations of polymer solution, i.e., 25, 50, and 100 mg/mL (n=6). Cells without treatment were selected as positive control whereas cells treated with Triton-X 100 (0.1% v/v) as negative control. Following 48 h of incubation, culture medium from the 96-well plate was substituted by 100 μL of serum-free medium containing 20 μL of MTS solution. Cells were then incubated at 37°C and 5% CO 2 for 4 h. After incubation, absorbance of each well was measured at 450 nm. Cell viability (%) was calculated by Eq. 1. LDH Assay. HCE or SV40 cells were seeded in 96-well plate at a density of 10 4 cells per well and incubated at 37°C, 5% CO 2 , and 98% humidity for 24 h. Polymer solutions were prepared in culture medium and sterilized by filtration with 0.2-μm syringe filters. Following incubation period, cells were exposed to various concentrations of polymer (25, 50 , and 100 mg/mL, n= 6) and incubated for 48 h. Cells without treatment were selected as negative control whereas cells treated with Triton-X 100 (0.1% v/v) as positive control. According to the protocol provided by the manufacturer, LDH release in cell supernatant was quantified by LDH assay kit (Takara Bio Inc., Japan). Samples were analyzed at an absorbance wavelength of 450 nm with 96-well plate reader. LDH (%) release was calculated by Eq. 2. Preparation of Nanomicelles (Method 1)
DEX-loaded nanomicelles, here on referred to as DEXM, were prepared by film hydration method. Calculated amount of polymer and DEX was accurately weighed out and dissolved in acetone/chloroform mixture (1:1). Organic solvents were evaporated under vacuum in a desiccator for 24 h to generate films. Films were then added with 1 mL of distilled deionized water (DDI) (65°C) and vortexed for 3 min. Nanomicellar solutions were syringe-filtered (0.22 μm) to separate undissolved DEX and subsequently analyzed for DEX content by reverse phase high-performance liquid chromatography (HPLC).
Exploratory Model (Experimental Design 1, ED 1)
In order to understand the factors and interactions influencing DEX solubilization in nanomicelles, a two-factor three-level response surface design (RSD) was employed. The factors under investigation were polymer amount (X1) and dexamethasone amount (X2) for their effects on DEX solubility (Y) in nanomicelles. The experimental design was generated with statistical design software SAS 9.02. The RSDsmall composite Hartley method was utilized for the aforementioned independent variables and dependent variables ( Table I ). The primary reason for selecting this design is the least number of runs as compared to other designs. The design had nine runs in total, including three center points. DEXloaded micelles were prepared by film hydration method (method 1).
Statistical Analysis. The influence of two factors (polymer (X1) and DEX (X2) amount) on one dependent variable was studied in an exploratory model. Hence, a statistical model with interactive and polynomial terms was used to evaluate their influence on the response variable (Y) (Eq. 3).
where Y is a response variable (DEX solubility, mg/mL); b0 represents the intercept; b1, b2, b3, b4, and b5 represent the regression coefficients for factor and interactions. X1 (polymer amount in mg) and X2 (DEX amount in mg) are individual effects. X1X1 and X2X2 are polynomial terms of individual effects, which represent the polymerpolymer and drug-drug interactions, respectively. X1X2 is the interaction term representing drug-polymer interaction.
Results from this design were analyzed with one-way analysis of variance (ANOVA). F test was carried out at α=0.05 to determine the significance of regression relationship between the response variable (Y) and a set of independent variables. Significant factors and interactions were identified by t test at 95% significance level. R 2 and adjusted R 2 were also calculated for the regression model. The model was validated by checking model assumptions and lack of fit test. Statistical analysis was performed with SAS 9.02 and JMP 9.0.
Preparation of Nanomicelles (Method 2)
Method 1 was modified based on the results obtained from exploratory model to obtained higher drug dissolution in nanomicelle core. The modified method is as follows. Briefly, drug and polymer films were obtained as described in method 1. The films were then heated at 65°C for 15 min to allow melting of the semicrystalline polymer. The melted films were added with 1 mL DDI water (37°C) and vortexed for ∼45 s. The solutions were allowed to cool down to RT and filtered through 0.22-μm syringe filters. Clear micellar solutions were analyzed for DEX solubility by reverse phase HPLC.
Predictive Model (Experimental Design 2, ED 2)
The primary goal of ED 2 was to predict optimal DEX/ polymer ratios providing DEX solubility of ≥1 mg/mL. Hence, ED 2 could also be referred to as the predictive model. We were also interested in delineating the effect of melting (micelle preparation method 2) on DEX solubility. RSD-small composite Hartley method described earlier was employed to achieve these goals (Table I) . Based on experiments with method 1, we considered that DEX solubility of 1 mg/mL would be a significant increase. Hence, DEX solubility of 1 mg/mL was set as optimal/target value. Statistical treatment described in earlier section was applied to this design as well. In addition, a reduced model was generated by removing insignificant effects. The reduced model was utilized to predict the DEX/polymer ratio providing optimal DEX solubility and validated by checking model assumptions, lack of fit test, and check point analysis.
Micelle Size, Polydispersity, and Surface Morphology
Mean micelle size and polydispersity index (PDI) were determined with Zeta Sizer (Zetasizer Nano ZS, Malvern Instruments Ltd, Worcestershire, UK) at RT. A 500-750-μL solution was used without any dilution. Morphology of nanomicelles was examined by transmission electron microscopy (TEM) (Philips CM12 STEM). About 50 μL of micellar solution was placed on a carbon-coated copper grid. The excess of solution was removed by Kimwipe. Samples were negatively stained by phosphotungstic acid and completely dried before taking TEM images.
Powder X-ray Diffraction (XRD)
XRD analysis was performed for DEX, polymer, dried DEX-polymer film and freeze dried DEXM formulation. A Rigaku MiniFlex powder automated X-ray diffractometer (Rigaku, The Woodland, TX, USA) was utilized for the analysis at RT. Cu Kα radiation (λ=1.5418 Å) at 30 Kv and 15 mA was utilized. The diffraction angle covered from 2ϴ 4.0°to 45.0°, and a step of 0.05°with 3 s/step was applied. The diffraction patterns were processed using Jade 8 (Materials Data, Inc., Livermore, CA).
In Vitro Release of DEX
The release mechanism for DEX from nanomicelles was determined by in vitro release study in simulated tear fluid (STF compositions: 2 g NaHCO 3 , 6.7 g NaCl, 0.08 g CaCl 2 ·2H 2 O, and deionized water was added up to 1 L, Tween-80 (0.5% w/w)) (22) with a dialysis method (23) (24) (25) . The optimal formulation obtained from the ED 2 was prepared and characterized for initial drug content. A five hundred-microliter micellar solution was added in a dialysis bag (MWCO 2,000 Da). The bag was tied at both ends and immersed in 10 mL of STF containing Tween-80 (0.5% w/w) at 37°C. The release medium was replaced with fresh STF at predetermined time points. The amount of DEX released was quantified by a reverse phase HPLC method. Release study was performed in triplicates. The results were plotted as mean±SD. The release data was fitted for zero-order, firstorder, Higuchi, and Korsmeyer-Peppas model to determine the kinetics of DEX release.
In Vitro Transport Across Conjunctival Cells
Transwell diffusion chamber system was utilized for determining in vitro permeability of DEX from DEXM across conjunctival cells following a published protocol. Cells were seeded at a density of 25,000 per well in 12-well collagen-coated Transwell® permeable inserts (Costar®) and grown until confluency by changing medium every alternate day. Prior to a transport experiment, cell monolayers grown on the Transwell® inserts were rinsed with Dulbecco's phosphate-buffered saline (DPBS) (pH 7.4) and incubated at 37°C for 10 min twice for both apical (AP) and basolateral (BL) sides. Transport was initiated by adding 400 μL of DEX suspension or DEXM (in DPBS, pH 7.4) to the donor chamber (AP side) of cells. DPBS pH 7.4 was added in receiver chamber (BL side). Transport experiment was conducted for 3 h. Samples (100 μL) were collected from the receiver chamber at predetermined time intervals of 15, 30, 45, 60, 90, 120, 150, and 180 min, and fresh DPBS pH 7.4 was replaced to maintain sink conditions in the receiver chamber. The samples were analyzed by liquid chromatography-mass spectrometry (LC-MS/MS) analysis following a previously published method from our laboratory (26) . Permeability (P app ) of DEX was calculated using Eq. 4.
where M represents the slope obtained from the plot of cumulative amount of drug permeated vs. time, A denotes the surface area of membrane exposed to drug, and C d is the drug concentration in donor chamber at t=0. Transport study was conducted in quadruplicate for all test and control sets. A statistical significance between the permeability of DEX suspension and DEXM at p<0.05 was considered to be significant.
Ex Vivo Transport Across the Sclera (23) Tissue Preparation. Adult New Zealand male rabbits weighing between 2 and 2.5 kg were obtained from Harlan laboratory. All animal handling procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of MissouriKansas City (UMKC, Kansas City, MO, USA). Rabbits were anesthetized with I.M. administration of ketamine HCl (35 mg/kg) and xylazine (5 mg/kg). The animals under deep anesthesia were euthanized by an overdose of sodium pentobarbital (100 mg/kg) administered through marginal ear vein. Eyes were removed carefully, and the posterior segment was separated by cutting along the limbus. Retina and choroid were separated from the sclera, and the sclera was placed in a petri dish containing Dulbecco's phosphate-buffered saline (pH 7.4).
In order to carry out permeability studies, the excised tissue was mounted on a Franz-type vertical diffusion cell (PermeGear Inc., Hellertown, PA, USA) with episcleral side facing the donor chamber. The receptor chamber was filled with isotonic phosphate-buffered saline (IPBS; pH 7.4). Dexamethasone suspension or DEXM formulation was added to the donor chamber to begin transport study. At a regular time interval, 200 μL of sample was withdrawn from the receptor chamber and replaced with an equal volume of fresh IPBS buffer. Experiments were carried under sink conditions for 3 h at 37°C in quadruplet. The samples were analyzed by LC-MS/MS following a method published previously from our laboratory (26) . Permeability (P app ) was calculated according to Eq. 4.
HPLC Method
Reverse phase HPLC method described earlier was used with necessary modifications (27) . Shimadzu LC pump (Waters, Milford, MA, USA) equipped with a UV detector (SPD-20AV, Shimadzu) was employed for the HPLC analysis. The mobile phase consisted of 65% tetrabutylammonium hydrogen sulfate (TBAHS) buffer and 35% acetonitrile (ACN) on a reverse phase C18 column (Phenomenex C18 Kinetex column 100×4.6 mm, 5 μm) as a stationary phase. Mobile phase flow rate was set at 0.4 mL/min. UV detector was set at 254 nm for quantifying DEX.
Analysis of DEX in Buffer Samples by LC-MS/MS
The LC-MS/MS method described earlier from our lab (26) was utilized with a few modifications for quantitating DEX in buffer samples from ex vivo transport studies. Ninety-microliter aliquots of buffer samples were spiked with 20 ng of prednisolone (IS) and vortexed for 15 s. The analytes were then extracted with 900 μL of ice-cold TBME and vortexed for 3.5 min. Samples were centrifuged at 10,000 rpm for 7 min to separate the aqueous and organic layers. Seven hundred and fifty microliters of the organic layer was collected and dried in vacuum. Dried sample was reconstituted in 100 μL of mobile phase (ACN/water::40:60, 0.1% formic acid). Ten microliters of reconstituted sample was injected onto the LC-MS/MS for analysis. LC/MS-MS QTrap® API-3200 mass spectrometer, equipped with Shimadzu quaternary pump, vacuum degasser, and autosampler (Shimadzu Scientific Instruments, Columbia, MD, USA), was employed to analyze samples from ex vivo studies.
HPLC separation was performed on an XTerra® MS C18 column 50 mm×4.6 mm, 5.0 μm (Waters, Milford, MA, USA). The mobile phase consisted of 40% ACN and 60% water with 0.1% formic acid, pumped at a flow rate of 0.25 mL/min. Multiple reaction monitoring (MRM) mode was utilized to detect the compounds of interest. The mass spectrometer was operated in the positive ion mode for detection. The precursors to product ions (Q1 → Q3) for DEX and IS during quantitative optimization were (m/z) 393.20→ 355.30 and 361.30 → 147.20, respectively. The operational parameters for the tandem mass spectrum for each analyte were obtained after running them in quantitative optimization mode. The turbo ion spray setting and collision gas pressure were optimized (IS voltage, ±5,500 V; temperature, 350°C; nebulizer gas, 40 psi; curtain gas, 30 psi). The lower limit of mL for DEX/ mL for DEX.
RESULTS AND DISCUSSION
Synthesis and Characterization of Polymer
Di-block polymer was synthesized by anionic ring opening polymerization using stannous octoate as the catalyst and mPEG as the initiator. Polymer was purified by cold ether precipitation and dried under vacuum. Structure of the polymer was confirmed by 1 H-NMR (Fig. 1a) and Fourier transform infrared spectroscopy (FTIR) spectroscopies. Proton NMR showed all the characteristic peaks for the polycaprolactone and mPEG residues. FTIR spectroscopy of polymer showed the presence of terminal alcohol at 3,441.09 cm − 1 and carbonyl group at 1,723.95 cm − 1
(Supplementary info Figure 1 ). Weight and number average molecular weights (Mw and Mn) and PDI were determined by gel permeation chromatography. Mw, Mn, and PDI were determined to be 4,586 Da, 3,155 Da, and 1.45, respectively. CMC was obtained by pyrene method in aqueous polymer solution (Supplementary info Figure 2 ). CMC for the polymer was 4.5 μg/mL, indicating good stability against dilutions.
XRD analysis for the polymer showed presence of characteristic peaks for polycaprolactone (PCL) and mPEG suggesting semicrystalline nature of the polymer (Fig. 2b) . Cytotoxicity studies of the new polymer were conducted on conjunctival and corneal cells, by MTS and LDH assays, prior to the development of formulation. Percent cell viability was calculated based on amount of formazione released for both HCE and SV40 cells (MTS assay) (Supplementary information Figure 3 ). Positive control (medium) and test groups were compared by ANOVA. No significant difference in %cell viability was observed at all polymer concentrations (ANOVA p>0.05). In addition, cytotoxicity study was also performed by LDH assay to confirm the results obtained from the MTS assay. Polymers interact with cells via cell membrane, and therefore, estimating the amount of LDH released in culture medium could be a preferred way to estimate the cell wall damage and thus cytotoxicity of polymers. LDH release for cells treated with polymer was compared to negative control (blank, medium). Based on ANOVA analysis, no significant difference in %LDH release was observed between blank and treatm e n t g r o u p s , i n b o t h H C E a n d S V 4 0 c e l l s (Supplementary information Figure 4 ).
Formulation Optimization
Exploratory Model (Experimental Design 1)
Preliminary experiments to prepare DEXM with film hydration method did not result in appreciable increase in solubility. Hence, a response surface methodology (small composite Hartley design) was employed to understand the influence of drug-polymer interactions on drug solubility in micelle core and identify the factors/interactions responsible for poor DEX loading in nanomicelles. The design runs (coded and uncoded runs) and corresponding DEX solubilities are presented in Table I . Solubility of DEX ranged from 0.18 to 0.37 mg/mL. Among all the runs, the highest solubility of DEX was observed for run no. 2 (0.37 mg/ mL), where both drug and polymer were at their highest levels (+1). Statistical treatment explained earlier was applied to analyze the data. Second-order least square equation for the master model is given by Eq. 5.
Master Model. Table II summarizes ANOVA, lack of fit, and correlation coefficient for the master model. The master model was found to be significant (p = 0.0155), indicating that solubility of DEX (Y) was considerably dependent on the set of X variables. The correlation coefficient (R 2 ) for the regression model was 0.9720. It means that the model explains 97.2% of variation in DEX solubility. Lack of fit p value of 0.5953 also suggested that the master model was significant and could predict DEX solubility. The model was also validated based on the plot of actual vs. predicted solubility (Supplementary information). A linear relationship was observed between actual DEX solubilities and solubilities predicted by the model with R 2 of 0.97. Also percent standard error of residual was found to be less than 10% for all the runs (Supplementary information), suggesting the model was significant. Reduced model was not generated since the aim of the exploratory model was to delineate the influence of the set of X variables on DEX solubility.
Estimated coefficients for each term (factors and interactions) with associated p values are presented in Supplementary information Table 1 . The estimated coefficients with p <0.05 were considered to be significant. Significant terms from the model were the amount of DEX (X2, p=0.0156), DEX-polymer interaction (X1X2, p=0.0069), and polymer-polymer interaction (X1X1, p= 0.0157) as indicated by Pareto chart (Fig. 3) . X1X1 had negative influence, while X1X2 and X2 had positive effect on DEX solubility. X2X2 also had negative effect on DEX solubility but the interaction was not significant (p=0.1236).
The response surface curve provides a diagrammatical representation of DEX solubility as a function of polymer and DEX amounts (Fig. 4) . The response surface was found to be nonplanar. Interestingly, increasing the polymer amount had variable effects on DEX solubility depending on the amount of DEX. For example, at a high level of DEX (+1 or 5 mg), raising the polymer amount had positive influence on solubility of DEX, as anticipated. The increase in DEX solubility could be attributed to enhanced DEX-polymer interaction (X1X2), which was the most significant term according to master model (p = 0.0069). Nonetheless, solubility increase was not linear; such nonlinearity could be attributed to X1X1 interaction in the dried film which may lower DEX solubility. On the contrary, increasing the polymer amount at low DEX level (−1 or 1 mg) resulted in a decrease in solubility. Moreover, the decline in solubility was steeper and nonlinear which may be explained by X1X1 interaction. At low level of DEX, X1X1 would be the dominant interaction compared to X1X2 which may explain the steeper decline in DEX solubility with an increase in X1.
To characterize the physical form of DEX and polymer, the dried polymer-DEX film was studied by XRD. Polymer/DEX film was prepared at a ratio X1:X2::30:5. XRD showed the presence of characteristic peaks of PCL (2θ=21.9) and mPEG (2θ=19.2 and 23.8) in the dried film (Fig. 4) , suggesting that the X1X1 interaction represents crystallization of the polymer upon evaporation of organic solvent. Small peaks corresponding to DEX were also present (2θ=14, 15.6, and 17) in the dried film, indicative of slight crystallization and X2X2 interaction. From the exploratory model, it can be concluded that solubility of DEX in micellar core is governed by polymer-DEX interaction (X1X2). We can also infer that polymer-polymer interaction (X1X1) occurs during solvent evaporation leading to significantly lower DEX entrapment. In order to improve DEX solubility, we need to overcome X1X1 interactions. In this case, X1X1 interaction represents the crystallization of polymer. We hypothesize that heating the dried polymer-DEX film above the melting point of polymer (t m = 60-62°C) may overcome X1X1 interaction (nanomicelle preparation method 2). Lowering X1X1 interaction may allow free polymer to interact with DEX thus maximizing DEX entrapment in micelle core.
Optimization Model (Experimental Design 2)
Based on our hypothesis, in order to overcome X1X1 interaction, we modified nanomicelle preparation method 1. A response surface design as explained earlier for exploratory model was generated for independent variables polymer amount (X1) and DEX amount (X2) and response variable 
Statistical parameters for the master model including parameter estimates, ANOVA for the master model, and lack of fit analysis are summarized in Table IV . The master model was found to be significant, based on model p value (p=0.0128), lack of fit p value (p=0.0901), and adjusted R 2 of 0.9345. The parameter estimates for master model are shown in Supplementary info Table 2 . According to the Pareto chart, only statistically significant factor was polymer amount (X1, p = 0.0026), unlike method 1 where polymer amount did not have any significant effect on DEX solubility (Fig. 5a ). This result may be attributed to melting of polymer in the film that allowed polymer to overcome X1X1 interaction, as we hypothesized. No influence of X1X1 interaction on drug solubility (p = 0.5858) was observed with modified film hydration method. XRD analysis of dried DEX-polymer film was conducted after heating the films to delineate the effect of heating on physical form of polymer. DEXpolymer film was prepared at 30:5::X1:X2 ratio. The peaks for mPEG-PCL were present despite heating the film at 65°C (Fig. 5) . These results could be explained by the fact that XRD patterns were recorded at RT. Gradual cooling of DEX-polymer film to RT could result in the recrystallization of polymer. It also worth noting that heating the film did not have any effect on the physical form of DEX, as predicted (Fig. 5a) .
Reduced Model. A reduced or predictive model was generated by removing the nonsignificant terms with p>0.05 from the master model. Hence, terms X1X2 and X1X1 were removed. XRD analysis indicated crystallization of DEX in polymer-DEX film (after heating) representing X2X2 interaction (Fig. 5) . In addition, removing the X2X2 interaction did Table 3 . Pareto chart for the reduced model is depicted in Fig. 5b . Again, the only significant term influencing DEX solubility was X1 (p= 0.0001). Interactions between DEX molecules (X2X2) were not significant (p=0.1673) as per model and, as expected, had negative effect on DEX solubility with method 2. Similar observation was noted for method 1 (exploratory model) suggesting that the melting has no influence on DEX crystallization. The prediction expression for reduced model is presented by Eq. 7,
Response surface showing the change in solubility of DEX as a function of DEX and polymer amounts is illustrated in Fig. 6 . Unlike the exploratory model, we were able to overcome the negative effect of X1X1 on DEX solubility with the modified method. Hence, the solubility of DEX increased linearly with increasing polymer amount at all the DEX levels.
Nonetheless, solubility increase was not linear with increasing DEX amount due to X2X2 interaction. In addition, despite the ratio for the DEX/polymer is the same in runs 1, 2, and 7, the amounts of polymer and DEX are different (Table V) . These different amounts resulted in variable solubility of DEX depending on the strength of DEX × DEX, polymer × DEX, and polymer × polymer interactions in the film upon drying. Hence, we see different solubilities for DEX at same DEX/polymer ratios. Furthermore, upon overcoming X1 × X1 interaction in optimized method 2, a significant enhancement in the solubility of DEX was observed (Tables V and VI) for the same amount of DEX and polymers. For example, the solubility of DEX was 0.37 and 1.13 mg/mL at 50 mg polymer and 5 mg DEX with methods 1 and 2, respectively (run no. 2 in Tables V and VI) .
The prediction profile was generated to determine the optimal point with the highest desirability (Supplementary info Figure 5 ). The check point analysis was carried out to validate the reduced model at X1:X2::20:2 ratio. Ratio X1:X2::20:2 was selected for check point analysis as it was not a part of design runs suggested by the statistical software (SAS 9.02). No statistically significant difference was observed between experimental and predicted DEX solubility (p>0.05) ( Table VI) .
The model was also validated by plotting predicted vs. actual solubility (Supplementary info Figure 6 ). The relationship was found to be linear with R 2 of 0.97 indicating predicted solubility by model is close to experimental one. The residuals Table III Table 4 . Standard error (%) was less than 10% for all the runs. Based on the check point analysis, percent standard error of residual, and experimental vs. predicted solubility, it was concluded that the reduced model can accurately predict DEX solubility. Using prediction profile for reduced model, optimal X1:X2 ratio to obtain DEX solubility ≥1 mg/mL was obtained.
Characterization of Formulation
Micelle Size and Morphology
Nanomicelle size and distribution were determined by dynamic light scattering method for all the runs in ED 2. The results are presented in Table VI . The size ranged from 26 to 28 nm with unimodel distribution irrespective of DEX solubility. The PDI for all the runs were below 0.23 indicating narrow size distribution. Size distribution showing mean size and PDI for design run no. 2 is illustrated in Fig. 7a . The average size was 27.32 nm with PDI of 0.125. It is expected that micelle size would increase with an increase in DEX solubility from 0.21 to 1.36 mg/mL. However, it is worth noting that even with this increase in solubility, drug loading did not vary appreciably (data not shown). Hence, we did not observe an appreciable increase in nanomicelle size or polydispersity with an increase in solubility. The morphology of optimal nanomicelle was studied by TEM (Fig. 7b) . TEM micrograph of nanomicelles indicated that the nanomicelles were spherical in shape.
H-NMR Spectroscopy of Blank Micelles and DEXM
Processes of micelle formation and DEX encapsulation in micelle core were studied with proton NMR spectroscopy. (Fig. 7) . During micelle formation, PCL block assembles to form the hydrophobic core and mPEG segment forms hydrophilic corona. Since the core of micelle lacks accessibility to solvent, movement of PCL segment in the core is limited and hence the proton NMR signal is very weak compared 1 H-NMR spectroscopy was also used to ascertain the presence of DEX in nanomicelle core. (Fig. 7) . The 1 H-NMR spectra for the combination of DEX and polymer in d 6 -DMSO showed all the characteristic peaks corresponding to DEX, PCL, and mPEG (Fig. 7) . 1 H-NMR for DEXM in D 2 O also showed the presence of characteristic peak for mPEG segment at 3.4-3.6 ppm and those for PCL were absent, indicating micellization. Characteristic peaks for DEX were absent due to restricted mobility inside micelle core, implying that drug was molecularly dispersed in micelle core (Fig. 7) .
Powder XRD Analysis of Blank Micelles and DEXM
Blank micelles and DEXM were also studied by XRD to seek further insight into physical state of polymer and DEX in nanomicelles. The results are presented in Fig. 7 . XRD pattern for freeze-dried DEXM was devoid of DEX peaks indicating that the drug was molecularly dispersed in nanomicelle. Both blank micelles and DEXM showed characteristic peaks for PCL at 2θ 19°and 23°. PCL, due to its semicrystalline nature, does not self-assemble in water to form micelles at RT. However, temperatures close to melting point provide PCL with necessary chain mobility to self-assemble into micelles. Once the micelles are formed and system reaches RT, PCL segments in core reestablish the polymer-polymer interactions regaining its semicrystalline state in nanomicelle core. We expect that the semicrystal nature of nanomicelle core would provide rigid core to the nanomicelles. Such rigid micelle core may provide resistance against sheer stress while transporting nanomicelles across the scleral pores. Rigidity has been shown to be beneficial for liposomal formulation during transport across the sclera (16) .
Release Kinetics of DEX
The release study was performed in simulated tear fluid at 37°C, under sink condition, to identify the mechanism of Fig. 8a . DEX release from the nanomicellar system lasted for 2.5 days. About 50% DEX was released by 24 h from nanomicelles. Previously, it has been shown that mPEG-PCL could sustain the release of hydrophobic agent such as honokiol (log p 5.21, polar surface area 40.46 (28)) for up to 2 weeks (29) . However, DEX is relatively polar molecule with log p of 1.68 and large polar surface area of 94.83 (30) . This may be responsible for poor interaction with hydrophobic PCL chains resulting in relatively faster release pattern.
Release data was fitted to zero-order, first-order, Higuchi, and Korsmeyer-Peppas model to determine the kinetics of DEX release. The best fit was found with the KorsmeyerPeppas model with an R 2 of 0.9998 compared to other models. The n value was calculated using the data points where less than 60% DEX was released. The n value was found to be 1.24 suggesting super case II transport as release mechanism. In super case II transport, drug release is controlled mainly by the polymer chain relaxation (31) . The polymer chain relaxation may result in the loss of DEXpolymer interaction which encapsulates DEX in micelle core. In addition, due to the semicrystalline nature of PCL chains, upon release of DEX from micelles, the polymer chain will have more freedom to align and form rigid crystalline core. Formation of rigid core upon release will also hinder the repartition of DEX back in nanomicelle core. Furthermore, the volume of release medium was 10 mL with Tween-80 (0.5% w/w) which would aid solubilization-released DEX. To further confirm super case II release mechanism, the fraction of drug release (Mt/Mi) as a function of square root of time (t 1/2 ) was plotted. The graph had a sigmoidal shape suggesting the mechanism was indeed super case II transport (Fig. 8b) .
In Vitro Transport Across Conjunctival Cells
We intend to use the nanomicelles for drug delivery to interior and posterior segment via topical administration. Hence, we also examined DEX transport across conjunctival cells (in vitro) and excised rabbit sclera (ex vivo). Figure 9 illustrates cumulative percent DEX transported across conjunctival cells from nanomicelles and suspension. The permeability of DEX with nanomicelles was 1.3E-06 cm/s, which was ∼2 times higher relative to DEX suspension (0.69E-06 cm/s).
Transscleral Permeability of DEX
The sclera acts as a static barrier for transport of drug/nanocarriers towards back of the eye following topical administration. Hence, transport of DEX across the excised rabbit sclera was carried out for the nanomicelles and compared with DEX suspension (0.1% w/v). Cumulative percent DEX vs. time profile for DEXM and DEX suspension is illustrated in Fig. 10 . The inset represents average permeabilities. A statistically significant increase in DEX permeability was observed with DEXM (P app =3.0E-06 cm/s) relative to DEX suspension (P app =1.19E-06 cm/s; p<0.05). A 2.5-fold increase in permeability with nanomicelles indicates a possible influence of nanomicelle size on DEX transport across the sclera. The increase in permeability with nanomicelles could be attributed to transport through the aqueous scleral pores (32) . We hypothesized that nanomicelles could improve the bioavailability of DEX in the uvea following the topical administration. Also, the conjunctival-scleral route could be of more importance compared to the corneal route in order to achieve higher intraocular levels. Conjunctival-scleral route could be favored due to high surface area and absence of tight junctions like in the cornea. Nanomicelles exhibited significantly high permeabilities for transport across the conjunctival cell line and sclera. Based on these preliminary experiments, we could suggest that there is a high possibility of achieving elevated DEX levels in the intraocular tissues (uveal track) via conjunctival-scleral route. In addition, the release of DEX from nanomicelles was relatively slower and lasted for more than 2 days. Thus, the frequency of topical administrations could also be reduced increasing patient compliance. However, further in vivo experiments are necessary to confirm this hypothesis. 
CONCLUSIONS
Small molecular weight di-block copolymer was successfully synthesized and characterized for its molecular weight, PDI, cytotoxicity on conjunctival and corneal cells, critical micelle concentration, and physical form. The micelle preparation method was optimized to achieve higher DEX solubility using exploratory model. Polymer-polymer interaction was found to be the prime cause of poor solubility of DEX in nanomicelles. Predictive model was generated to determine DEX and polymer amounts to achieve optimal formulation with 0.1% w/v DEX solubility. Modified film hydration method significantly enhanced the DEX entrapment in nanomicelles by overcoming the negative influence of polymer crystallization. Optimal nanomicelles were spherical in shape with unimodel size distribution. The data from ex vivo permeability and rigid nanomicelle core indicate that these nanomicelles may have the potential to deliver DEX and other hydrophobic anti-inflammatory agents such as rapamycin to the back of the eye following topical route for the treatment of intermediate to posterior segment uveitis. In further studies, we aim to prepare nanomicelles of various sizes using DOE. Furthermore, the effects of nanomicelle size on transport across the excised rabbit sclera will be determined for their potential to deliver drugs to the intermediate and posterior segments following topical administration. The nanomicelles of optimal size will also be tested in an in vivo rabbit model to confirm the efficacy of the optimal formulation.
